EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society

Raj S Padwal iD, Michael Dorsch, Sheldon Tobe, Jennifer Ringrose, Ernesto L Schiffrin iD, Ross D Feldman, Bhanu Prasad, Alexander A Leung, Lisa Dubrofsky, Karen C Tran, Mina Madan, Lindsay Machan und 1 weitere

American Journal of Hypertension · 2025

DOI: 10.1093/ajh/hpaf236 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Raj S Padwal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Hypertension, Sympathectomy, Kidney, Blood Pressure. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over one-third of Canadians with hypertension do not achieve recommended blood pressure (BP) targets despite availability of effective treatments. Renal sympathetic nerve denervation (RDN) is a recently approved, minimally invasive treatment for hypertension being offered in multiple Canadian centers. How best to implement this procedure in contemporary Canadian clinical practice remains unclear. Herein, we provide a Canadian hypertension specialist viewpoint on use of RDN in Canada. We review the rationale for, and evidence supporting, the use of RDN and discuss, using 2 clinical cases, its potential therapeutic role. We note that RDN has effectively lowered BP in multiple, sham-controlled, randomized clinical trials and has a favorable safety profile. Economic models indicate that it is cost-effective in the Canadian context. Conversely, the BP-lowering effect is relatively modest; no well-established method to pre-identify responders exists; cardiovascular endpoint data supporting use of RDN are lacking; and no clear funding model is currently in place in Canada. Accordingly, we suggest that use of RDN be reserved for willing patients with severely elevated BP despite the use of first-line conventional therapies who have had secondary causes excluded. Examples include patients with resistant hypertension or moderate or severe hypertension and multiple drug intolerance syndrome. In view of its recent approval and known operator-dependency, RDN should be offered solely through programmatic, multidisciplinary collaboration between hypertension specialists and experienced interventionalists using a shared decision-making approach with the patient. Funding deployment should target such programs and sites should carefully monitor their outcomes to confirm comparability to the published literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionSympathectomyKidneyBlood PressureHumansCanadaTreatment OutcomeMaleMiddle AgedFemaleAgedAntihypertensive Agents

Stichwörter der Autor:innen

blood pressurecase reportrenal denervationresistant hypertension

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Alberta, Edmonton, AB, Canada.
  • Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Department of Medicine, Northern Ontario School of Medicine, ON, Thunder Bay, Ontario, Canada.
  • Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montréal, QC, Canada.
  • Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montréal, QC, Canada.
  • Department of Medicine, University of Western Ontario, London, ON, Canada.

ORCID-Profile: Raj S Padwal, Ernesto L Schiffrin

Zitieren

APA

Padwal, R. S., Dorsch, M., Tobe, S., Ringrose, J., Schiffrin, E. L., Feldman, R. D., Prasad, B., Leung, A. A., Dubrofsky, L., Tran, K. C., Madan, M., Machan, L., & Khan, N. (2025). The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf236

Vancouver

Padwal RS, Dorsch M, Tobe S, Ringrose J, Schiffrin EL, Feldman RD, et al. The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf236

BibTeX
@article{Padwal2025,
  author = {Padwal, Raj S and Dorsch, Michael and Tobe, Sheldon and Ringrose, Jennifer and Schiffrin, Ernesto L and Feldman, Ross D and Prasad, Bhanu and Leung, Alexander A and Dubrofsky, Lisa and Tran, Karen C and Madan, Mina and Machan, Lindsay and Khan, Nadia},
  title = {The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society},
  journal = {American Journal of Hypertension},
  year = {2025},
  doi = {10.1093/ajh/hpaf236}
}
Kostenlos starten →